Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010

Kudo, Masatoshi

doi:10.1159/000315239

Cited by 126 publications

(78 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some authors suggest that RFA is a curative treatment for HCCs under 3 cm with 4 years survival rate over 65% (38,39).…”

Section: Ablative Therapymentioning

confidence: 99%

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Grigorie¹,

Alexandrescu²,

Smira³

et al. 2017

chr

View full text Add to dashboard Cite

RezumatObiectivul acestui studiu este acela de a evalua rezultatele pacienţilor trataţi pentru hepatocarcinom (CHC) într-un centru de Chirurgie Generalã şi Transplant Hepatic. Material şi metode: Acest studiu retrospectiv include 844 pacienţi diagnosticaţi cu CHC şi trataţi chirurgical cu intenţie de radicalitate. Singurele metode de tratament curativ pentru CHC, la ora actualã sunt reprezentate de rezecţia hepaticã (RH) şi transplantul hepatic (TH). Ablaţia tumoralã poate fi indicatã în tratamentul CHC precoce, în cazurile la care rezecţia sau transplantul hepatic nu se pot efectua. La 518 pacienţi s-a practicat rezecţie hepaticã, 162 au beneficiat de transplant hepatic, iar 164 pacienţi au fost trataţi prin distrucţie cu radiofrecvenţã (RFA). 615 pacienţi (73%) au prezentat cirozã hepaticã. Rezultate: Morbiditatea şi mortalitatea înregistrate pentru întreg lotul de pacienţi au fost de 30% şi respectiv 4,3%. Supravieţuirea la 5 ani a fost de 39% cu diferenţe semnificative statistic între pacienţii la care s-a practicat RH comparativ cu cei transplantaţi şi Chirurgia (2017)

show abstract

“…Some authors suggest that RFA is a curative treatment for HCCs under 3 cm with 4 years survival rate over 65% (38,39).…”

Section: Ablative Therapymentioning

confidence: 99%

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Grigorie¹,

Alexandrescu²,

Smira³

et al. 2017

chr

View full text Add to dashboard Cite

show abstract

“…In spite of the development of various treatments for HCCs, such as, surgical resection and transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI) and percutaneous radiofrequency (RFA), the 5-year survival rate for all stages of HCC has remained less than 60% (1,2). In general, prognostic evaluation is mainly based on the clinical factors, such as, histopathological stage, clinical stage, tumor size, and tumor numbers.…”

Section: Introductionmentioning

confidence: 99%

Frequent loss of p19INK4D expression in hepatocellular carcinoma: relationship to tumor differentiation and patient survival

Morishita

Ju²,

Deguchi³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. p19INK4D belongs to the family of cyclin-dependent kinase inhibitors (CdkIs) that target the cyclin-dependent kinases and inhibit their catalytic activity. The role of p19 INK4D in cell cycle progression in hepatocellular carcinoma (HCC) is poorly characterized. The aim of this study was to examine the expression of p19 INK4D IntroductionHepatocellular carcinoma (HCC) is one of the major causes of cancer-related death due to its high frequency and poor prognosis. In spite of the development of various treatments for HCCs, such as, surgical resection and transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI) and percutaneous radiofrequency (RFA), the 5-year survival rate for all stages of HCC has remained less than 60% (1,2). In general, prognostic evaluation is mainly based on the clinical factors, such as, histopathological stage, clinical stage, tumor size, and tumor numbers. In addition, some studies (3,4) including our reports (5,6) have suggested that other factors, such as the molecular characteristics of the tumor, may offer novel approaches to the identification of groups of patients that could benefit from more aggressive treatment.Cyclins, cyclin dependent kinase (Cdk) and Cdk inhibitors (CdkIs) are frequently altered in human cancers (7-9). In mammalian cells, to date, at least 2 distinct families of CdkIs are known. The inhibitor of Cdk4 (INK4) , which specifically inhibit cyclin D-related kinase activity by binding to . The other known CdkI family, the p21 family, consists of p21, p27 KIP1, and p57 KIP2 , which are general inhibitors of the G1 to S transition in the cell cycle (13,15). At clinical involvement, the loss of the expression of KIP family members' p21 CIP1 , and p27 KIP1 has recently been shown to be associated with poor prognosis for various human cancers (16-21). p57 KIP2 is also correlated with the differentiation and prognosis for patients with HCC (5). p16 INK4A and p19 INK4D, members of the INK4 family, are the most extensively studied in various human cancers including HCC with respect to the clinical significance (3,4,12,14,22

show abstract

“…Defect reperfusion imaging also has a wide range of applications, allowing screening for HCC in cirrhotic livers with coarse hepatic parenchyma [11], diagnosis of malignant grade, identification of the site of local tumor progression after treatment [21,22], and US-guided needle puncture [22,23,24,25] (fig. 3).…”

Section: Advances In Usmentioning

confidence: 99%

Diagnostic Imaging of Hepatocellular Carcinoma: Recent Progress

Kudo

2011

Oncology

Self Cite

View full text Add to dashboard Cite

The diagnostic imaging of hepatocellular carcinoma (HCC) has recently undergone marked progress. The advent of the ultrasound (US) contrast agent Sonazoid, approved in January 2007, and magnetic resonance imaging (MRI) with the liver-specific MRI contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA-MRI), approved in January 2008, are of particular significance. Sonazoid contrast-enhanced US (Sonazoid-CEUS) is useful not only for the diagnosis of HCC, but also for guiding treatment and assessing treatment response. Sonazoid-CEUS has proven to be particularly effective for screening and staging, which used to be considered impossible with CEUS, through the introduction of the newly developed diagnostic technique of defect reperfusion imaging. It is still not possible if other vascular agents such as SonoVue and Definity are used. In particular, Gd–EOB-DTPA-MRI has been suggested to be much more reliable in the differentiation of early HCC from precancerous dysplastic nodules than any other modalities such as multidetector raw computed tomography, dynamic MRI, and superparamagnetic iron oxide-MRI. A decrease in contrast uptake in the hepatocyte phase observed on EOB-MRI is strongly suggestive of cancer, and the absence of early staining in the arterial phase suggests early HCC. The differential diagnostic capacity of Gd-EOB-DTPA-MRI is considered to far exceed that of what were previously the most useful imaging techniques, computed tomography (CT) during hepatic arteriography or CT during arterial portography, and to be comparable to that of the pathological diagnosis by pathologists specialized in liver.

show abstract

Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010

Cited by 126 publications

References 163 publications

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Frequent loss of p19INK4D expression in hepatocellular carcinoma: relationship to tumor differentiation and patient survival

Diagnostic Imaging of Hepatocellular Carcinoma: Recent Progress

Contact Info

Product

Resources

About